| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8615703 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 9 Pages |
Abstract
The use of consolidative RT after HDC and ASCT for relapsed or refractory DLBCL appears to significantly improve LRC. For patients with masses ⥠2 cm after ASCT, improved 2-year PFS and OS were seen. Prospective trials are needed to further identify the patients who would derive the most benefit from consolidative RT in the ASCT setting.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Brendan G. Coutu, Christopher T. Wilke, Jianling Yuan, Qing Cao, Matthew R. Vernon, Chung Lee, Veronika Bachanova, Kathryn E. Dusenbery,